A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease
Relative to FCM, fewer infusions of FDI were required, there was no need for phosphate monitoring, and disease-related QoL was improved, while overall costs were reduced.
Authors
- Neesha Nanu (ORCID: https://orcid.org/0000-0002-3817-3463)
- Hans Strid (ORCID: https://orcid.org/0000-0003-4651-6769)
- Henrik Hjortswang (ORCID: https://orcid.org/0000-0001-6352-5419)
- Stefan Lindgren
- Richard Fulton Pollock (ORCID: https://orcid.org/0000-0002-9873-7507)
- Bardh Manxhuka
Institutions
- Karolinska University Hospital (SE)
- Lund University (SE)
- Swedish Institute for Health Economics (SE)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1080/13696998.2025.2487359
- Citations
- 4
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 7.08